NTRA | tickerfilter.com

Fundamental analysis

24%

Profitability 8%

Dept financing 11%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

7.45%

1 Month

-17.81%

3 Months

-16.56%

6 Months

9.90%

1 Year

62.48%

2 Year

152.54%

Key data

Stock price

$142.51

P/E Ratio

0.00

DAY RANGE

$137.24 - $144.40

EPS

-$2.02

52 WEEK RANGE

$83.13 - $183.00

52 WEEK CHANGE

$59.19

MARKET CAP

20.899 B

YIELD

N/A

SHARES OUTSTANDING

123.681 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.02

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,421,180

AVERAGE 30 VOLUME

$2,331,181

Company detail

CEO: Stephen Chapman
Region: US
Website: natera.com
Employees: 3,020
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage.

NTRA - Natera, Inc.